

AMYLOIDOSIS CENTER REPORT

FALL 2015 | ISSUE 29
www.bu.edu/amyloid

FROM THE DIRECTOR

December, 2015

Dear Friends,

This year was sad for us with Dr. David Seldin's death due to cancer in June, but we go forward with the legacy he left us and our mission to develop better treatments and cures for amyloid diseases. Dr. Seldin was part of our group as a hematology/oncology doctor and basic science researcher since 1994, and was the director of the Amyloidosis Center since 2007. We miss his expertise in the direction of our basic research. We miss his guiding hand in the advancement of our stem cell transplant program and the evaluation of the clinical trials we offer. Most of all we miss his gentle nature, his happy laugh, and his warm friendship.

As we go forward, Dr. Vaishali Sanchorawala has been appointed the Associate Director of our Center by Dean Karen Antman of Boston University School of Medicine, and I will serve as Interim Director. Dr. Sanchorawala, a hematologist and oncologist, has been part of our Center since 1994. She was a key physician in developing the high-dose chemotherapy and stem cell transplant treatment for AL amyloidosis and is currently the director of the Stem Cell Transplantation Program. She is an active participant in the development of multi-centered treatment clinical trials and internationally recognized as a leader for the treatment of AL amyloidosis.

In this issue, we will highlight the clinical trials that are taking place in our clinic. In the past few years, we have been able to offer patients with AL and ATTR amyloidosis a number of opportunities to participate in a clinical trial. Many trials are undertaken in partnership with pharmaceutical companies. And some of the trials are "investigator initiated", meaning the trial was developed by amyloid doctors to answer a question that was prompted by laboratory data or a clinical finding presented by patients. [Please see pages 2-4 for information on our current trials.](#)

The research team in the Alan and Sandra Gerry Amyloidosis Laboratory, under the direction of Dr. Lawreen Connors, continues its outstanding work to find clues and answers to why and how misfolded proteins form amyloid fibrils. This year, we are proud to note that one of Dr. Connors' graduate students, Clarissa Koch, received her Ph.D. in amyloid studies and will go to Northwestern University in Chicago for post-doctoral work. [For a report on our research activities see page 5.](#)

In Dr. Seldin's memory, we have set up an endowment fund to help support young investigators who are doing research on amyloidosis. Students were close to Dr. Seldin's heart and he recognized the importance of training young scientists to work on amyloid diseases. The endowment is named the "David C. Seldin M.D., Ph.D. Amyloid Research Training Fund". Many of you have already contributed to the Fund and we are very grateful. [See the report on pages 8-9.](#)

Two new physicians have joined the amyloid clinical team this year. Dr. Cindy Varga has joined the section of hematology/oncology of Boston Medical Center and will be a consultant for our patients in clinic. Dr. Varga has a special interest in hematologic malignancies and plasma cell dyscrasia including AL amyloidosis and multiple myeloma. Dr. Hassan Yameen is a new amyloid internist joining the team to see patients as they come to the clinic and to guide them through their evaluation.

We thank you for your steadfast and generous support of our Center. We wish you good holidays with family and friends, and hope your next year will be healthy and happy. ■

Sincerely yours,



Dr. Vaishali Sanchorawala



Dr. Lawreen Connors




Dr. John Berk



Dr. Martha Skinner





CLINICAL TRIALS FOR AL AMYLOIDOSIS

By Vaishali Sanchorawala, M.D.

What is a clinical trial?

A clinical trial uses a device, drug or combination of drugs to find out if it is safe, effective, or possibly better than medications that are currently available for a disease. Clinical trials are often called research studies. These studies follow each patient over the course of time, using study drugs and documenting their safety, effectiveness, as well as other information to better understand either the drug, disease, or both.

Why should you participate in a clinical trial?

Clinical trials play an important role in the development of new drugs to treat specific diseases, and are vitally important for rare diseases, such as AL amyloidosis. Many of the drugs we see today, were first tested in research studies—including lenalidomide, bortezomib, and even high-dose melphalan and autologous stem cell transplantation! Without the participation of volunteers in these clinical trials, we may have never known the powerful properties of these drugs and their effectiveness. At Boston Medical Center and Boston University Amyloidosis Center, we are proud to have led the way in all of these foundational trials.

We are also excited to be able to offer patients with AL Amyloidosis promising new study drugs, including the proteasome inhibitor Ixazomib first-in-class fibril disrupting monoclonal antibody, only recently available and only in clinical trials.

Clinical Trials Team for AL Amyloidosis

Hematologists: Vaishali Sanchorawala, J. Mark Sloan, and Cindy Varga

Clinical research nurse: Anthony C. Shelton

Clinical research and stem cell transplant nurse practitioner: Dina Brauneis

Stem cell transplant coordinator: Taylor Teschner

Clinical research associates: Stephen Lo, Jill McRae

Clinical trials administrative director: Salli Fennessey



Clinical Trials Team for AL Amyloidosis

Front row: Dr. Cindy Varga, Taylor Teschner

Back row: Anthony Shelton, Dr. Vaishali Sanchorawala, Salli Fennessey, Dina Brauneis, Dr. Mark Sloan

Clinical trials available for AL amyloidosis at Boston Amyloidosis Center

IRB #H-33808/Velcade Randomized: Phase III Trial of High-Dose Melphalan and Stem Cell Transplantation vs High-Dose Melphalan and Bortezomib and Stem Cell Transplantation in Patients with AL Amyloidosis/ ClinicalTrials.gov Identifier NCT02489500

IRB #H-31082/Pomalidomide: A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects with Previously-Treated AL Amyloidosis/ ClinicalTrials.gov Identifier: NCT01570387

IRB #H-32790/AMyC 11-MM-02: A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis/ClinicalTrials.gov Identifier: NCT01789242

IRB #31928/CUMC: Phase II Study of the Combination of Bendamustine and Dexamethasone in Patients with Relapsed AL Amyloidosis/ClinicalTrials.gov Identifier NCT01222260

WIRB #2012-1122/Millennium C16011: A Phase III, Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis/ClinicalTrials.gov Identifier NCT01659658

IRB #H-32377/Karmanos #2011-155: Phase I Study of Pomalidomide, Bortezomib, and Dexamethasone (PVD) as First-Line Treatment of AL Amyloidosis or Light Chain Deposition Disease/ClinicalTrials.gov Identifier NCT01728259

WIRB #2015-0681/Prothena Neotope CL002: A Phase 3 Randomized, Multicenter, Double-Blind, Placebo Controlled, 2-Arm Efficacy and Safety Study of NEOD001 Plus Standard of Care vs. Placebo Plus Standard of Care in Subjects with Light Chain (AL) Amyloidosis/ ClinicalTrials.gov Identifier NCT02312206

IRB #H-34138/Gilead IdALAMP: A Idelalisib for IgM-Associated AL Amyloidosis (Approval Pending) ClinicalTrials.gov Identifier: Pending

Results of Stem Cell Transplant Clinical Trials

Some of you have participated in several sequential institutional review board-approved clinical trials of high dose chemotherapy and stem cell transplantation during the past 20-years. This experience was recently published as a correspondence in the journal, Blood. (Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20 year experience. Sanchorawala V, Sun F, Quillen K, Sloan JM, Berk JL, Seldin DC. Blood. Nov. 12, 2015 pp 2345-2347. Please let us know if you would like a copy of this landmark paper.

Words from our patients about Clinical Trials Participation

"In August 2015, I completed my second clinical trial through the Amyloidosis Clinic at BMC. Before entering into each trial, I gave the situation careful and thorough consideration. My clinical trials research nurse and doctors explained things in depth. They diligently answered each of my questions in face to face conversations as well as answering all my phone calls and emails. Their care throughout these trials was exemplary. I experienced minimal to no side effects in both trials. My total response by the conclusion of each trial was excellent. Each clinical trial was a positive experience resulting in improved health." *Jean Boshco*


"I was officially diagnosed with AL Amyloidosis in January 2005 and was treated with high dose chemotherapy and a stem cell transplant. I had a complete response (hematologic and clinical) at one year. At my second annual evaluation in 2007, I had a biochemical recurrence (elevated free light chains and positive urine immunofixation) without further clinical involvement of any organ system. Since then I have had six different treatments each providing me with partial or complete response followed by rise in free light chains except for the last treatment. Now, I have been off treatment with normal free light chains for almost 15 months.

Of the last six treatments, five have been clinical trials. Each clinical trial raised questions regarding risks and benefits. Study drugs may have more complications as the correct dose and safety parameters are being determined. There are also more frequent lab tests and imaging studies with clinical studies compared with standard treatments.

I chose to volunteer for clinical trials for two very important reasons. One is that there are only a small number of approved drugs for treating AL Amyloidosis, and I am able to expand my choices for treatment if I qualify for a study. Second because amyloid is a rare disease, accumulating enough patients for statistical significance of study results is difficult (or even impossible in some cases). I feel, as a patient, I want to contribute to the body of knowledge regarding treatment effectiveness so that in the future other patients with this disease will benefit from the additional choices of drugs." *Dr. Harold Forbes*

"Thanks to the fact that I chose to participate in the clinical trial, to the dedication of Dr. Sanchorawala and her outstanding team, and to the dedication and thoroughness of my husband as caregiver, I am proud to say that my amyloidosis is in complete response. I feel good and can enjoy my life and my work as a college professor today. I have been back at work full time since fall 2012. I am 61 and do not expect to retire any earlier than age 66. I am very aware that had I not had the excellent treatment I had at Boston Medical Center, I might be either very ill today, or possibly no longer alive." *Prof. Katherine Rowan*

continued on page 4



CLINICAL TRIALS FOR FAMILIAL AMYLOIDOSIS

By John Berk, M.D.

ATTR Clinical Trials

The transthyretin amyloid (ATTR) clinical trials group has grown to include 3 clinical coordinators, a cardiologist (Dr. Ruberg), a neurologist (Dr. Wiesman), and the principal investigator of the Diflunisal Trial (Dr. Berk). Our clinical coordinators, Caitlin Brueckner, Victoria Lattanzi, and Victoria Lazzari, collectively provide years of clinical trials experience from Brown University Medical Center, Boston Medical Center, and industry research activities. Pharmaceutical sponsors repeatedly cite their care of subjects, data collection, and records management as the standard by which other research centers should be measured.


The studies in which the ATTR clinical trials group is actively involved include:

- **Doxycycline Study (Boston Medical Center)** -- Safety and Effect of Doxycycline in Patients With Amyloidosis (NCT01677286) Enrollment closed, data collection complete. Analysis underway.
- **Kiacta AA amyloid Study (CT Development of America, Inc)** -- Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis (NCT01215747): enrollment closed, data collection nearing completion. Analysis will not begin until mid-2016 at the earliest.
- **Isis phase III ATTR polyneuropathy study (Isis Pharmaceuticals, Inc.)** -- Efficacy and Safety of ISIS-TTR Rx in Familial Amyloid Polyneuropathy (NCT01737398): Nearing enrollment completion, data collection ongoing for another ~18 months.
- **Amylam phase III ATTR polyneuropathy study (Amylam Pharmaceuticals, Inc.)** -- APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis (NCT01960348). Nearing enrollment completion, data collection ongoing for another ~18 months.
- **Amylam phase III ATTR cardiomyopathy study (Amylam Pharmaceuticals, Inc.)** -- ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) (NCT02319005): Recruiting subjects.


Drug development for ATTR disease is in a period of unprecedented growth. In the space of 10 years we have gone from liver transplantation as the only treatment option for familial TTR amyloidosis to the discovery of TTR protein stabilizers (diflunisal/tafamidis) and, now, TTR gene silencing agents.

With your partnership, we can establish multiple medical treatments for people challenged by ATTR amyloid – now and for future generations.

We would be delighted to field questions about these trials and to discuss the candidacy of interested patients for the studies with continuing enrollment. Please contact us if you have any questions. ■



Familial Amyloidosis Clinical Trials Team
Front row: Victoria Lattanzi, Caitlin Brueckner
Back row: Dr. Janice Wiesman, Victoria Lazzari, Dr. John Berk, Dr. Frederick Ruberg



Dr. John Berk and Dr. Frederick Ruberg

This has been an eventful year with ups and downs for all of us in the Gerry Amyloid Laboratory as members of the Amyloidosis Center team. Personal triumphs have included research presentations, manuscript publications, and graduations. Conversely, we have experienced great sadness in the untimely and tragic death of our director, Dr. David C. Seldin. In his memory, we remain strong and firmly committed to our research studies aimed at advancing the current understanding of amyloidosis. As a group of dedicated research scientists, graduate and post-doctoral students, and laboratory technical assistants, we continue the mission espoused by Dr. Seldin to find better treatments, improve diagnosis, and ultimately develop cures for these devastating amyloid diseases.

Our investigations focus on deciphering the molecular basis of amyloidosis. With the use a variety of model systems and highly technical instrumentation, and vital collaborations with affiliated laboratories at Boston University School of Medicine, we study the way genes and proteins lead to amyloid deposits, how protein aggregation occurs, and how amyloid deposition leads to cell and tissue damage in immunoglobulin light chain (AL) and transthyretin (ATTR) forms of amyloidosis. The model systems we use range from patient-specific stem cells to heart cell lines to animal models. Data from our studies will help us to better define amyloid onset and progression pathways, and direct us to therapeutic strategies that will slow, halt, and eradicate amyloidosis.

Highlights of the past year included graduations in May of Clarissa M. Koch and Gloria Chan. Clarissa, an international student from Amsterdam, received a PhD in Pathology after successfully defending her thesis research entitled, "Characterizing the Effect of Transthyretin Amyloid on the Heart." She showed that cardiac cells, including reprogrammed patient-specific induced pluripotent stem (iPS) cells from patient blood have a toxic response to aggregated forms of TTR and this toxicity can be inhibited with the antibiotic, doxycycline. Gloria, a biochemical research assistant who has worked with Dr. Connors since 2011, received an MS in Bioinformatics. Dr. Michael J. Greene, a former doctoral and post-doctoral trainee in the Gerry Lab, had his work demonstrating that clusterin can modulate TTR amyloid fibril formation published in *Biochemistry* (<http://www.ncbi.nlm.nih.gov/pubmed/25478940>). In addition, Jacquelyn Sikora Hansen, a Pathology doctoral graduate student in the lab, had some of her recent genetic studies of ATTRwt published in the journal, *Human Genetics* (<http://www.ncbi.nlm.nih.gov/pubmed/25367359>). Dr. Tatiana Prokaeva was invited to give a presentation at the 7th International Symposium: Clinical Applications of Free Light Chain

and Heavy/Light Chain Analysis which was held in Edinburgh, Scotland (April 2015). Lastly, Dr. Connors presented a talk entitled "The Translational Science of Transthyretin-associated Cardiomyopathies – Current Clinical and Basic Science Research" at the American Society for Investigational Pathology/Experimental Biology Meeting held this past March in Boston (<https://asip.org/meetings/2015/>). ■



Gerry Laboratory Team, June 2015
Jacquelyn Sikora Hanson, Dr. Haili Cui, Gloria Chan, Dr. Lawreen Connors, Clarissa Koch, Dr. Tatiana Prokaeva, Brian Spencer, and Dr. Elena Klimtchuk



Drs. Clarissa Koch and Lawreen Connors, May 2015



Drs. Connors, Seldin, and Sanchorawala, June 2014

Reva Dolobowsky - The "Informed Messenger"

Reva Dolobowsky has been coming each week to the Amyloidosis Clinic, for the past 2 years. She has become a credentialed volunteer at Boston Medical Center. When asked why she volunteers she replied "I come to make it more comfortable and a less stressful place for the patients." She enters the waiting room not knowing what to expect, as the patients change each week. This, she adds, is the exciting part as she has to figure out how to make people comfortable.

The Amyloidosis Clinic has 15-20 patients each week, either for a new or a follow-up evaluation. Reva introduces herself and makes her way around the waiting room, answering questions and chatting with each patient and their family. She explains that she is not a health professional, but her husband is a patient and they went through this process. She answers questions varying from where to eat lunch, dinner, to how to navigate to the different appointments they might have.



Reva Dolobowsky

Reva recalls that the first time she came to the clinic with her husband was "very scary." She remembers being touched by speaking with someone in the waiting room who told her that she would pray for her. Reva said that she made it a point to remind all of her husband's health care providers that he is a regular person and not the medical record number or a disease. It is this sense of humanity that she tries to impart each week to the patients when she chats with them. Each patient has an amazing story about how they found out about their disease and the Amyloidosis Center, but each story is different from the next. Occasionally people will cry, being overcome with a multitude of emotions, and

she tries to be as reassuring as she can. Surprisingly, there have been only a few instances where someone declined to speak with her. "It's like an improv act," Reva says, "each week is different". Her husband has come back to the Amyloidosis Center a number of times. "And some follow-up evaluations", Reva said, "are tougher than others because the feeling in the waiting room is different". She looks around and sees some people chatting while others are looking fearful and clutch the handles of their seats. She thought to herself, "Wouldn't it be nice if there was an icebreaker?" While waiting to see their various physicians having someone to chat with to take their minds off their situation, albeit temporarily, would be a good distraction. This idea was the beginning of her volunteer work in our clinic.

She wanted to give back to the Amyloidosis Center because she is so grateful for the help that we are providing to her husband. While pondering what she could do, she remembered a particular visit to the clinic. She remembers an occasion where someone had a child about 5 or 6 years old with them in the waiting room. This child helped everyone in the waiting room by doing just what children do, he worked the room and was disarming! He casually walked around talking with different people and Reva felt the mood lighten. What a young source of inspiration!

She did not know how the idea would be received. She approached Dr. Vaishali Sanchorawala who supported her idea enthusiastically. And now she is in her second year as a volunteer in the Amyloidosis Clinic. I asked Reva what, if anything, in her background prepared her for this type of service. I found out that she managed a market research consulting company for a number of years. This type of research, focus groups, required her to quickly make a connection with total strangers to get them to open up quickly about various topics. It provided her with the expertise that the basis for her service is built on. She sees her role as a facilitator, helping to share information that she and other patients have discovered while here for their respective evaluations.

She heard the term "informed messenger" a few years back and thinks of herself as our "informed messenger" – someone who has experience with the process firsthand and has come to help, inform and comfort others. ■


David C. Seldin, M.D., Ph.D.

Dr. Seldin took special pleasure in working with students and young investigators. He had an extraordinary ability to critique their work respectfully and encourage them to strive for the best. He developed and was the first director of the graduate program in Molecular Medicine in the Division of Graduate Medical Sciences at Boston University, and established courses for graduate students in Cancer Biology and in Diseases of Protein Misfolding. He enjoyed training and mentoring a generation of physicians and post-doctoral and pre-doctoral fellows in the conduct of clinical, laboratory and translational research.


In his memory we have established a fund to support young investigators studying amyloid disease. We are very grateful to so many of you that have contributed. Our immediate goal is to reach \$100,000. We are almost there. As of now, we have reached more than \$70,000 from 160+ donors. Our heartfelt thanks to all of you! ■



Dr. Vaishali Sanchorawala in clinical meeting



Gloria Chan, Amyloid Laboratory




Drs. Carl O'Hara and John Berk, Amyloid Laboratory



Dr. Cindy Varga



Dr. Allison Rosenberg



AMYLOIDOSIS CENTER DONOR LIST

2013-2015

The Amyloidosis Center at Boston University School of Medicine is pleased to recognize the generosity of its many donors whose support has assisted us in enhancing and continuing our progress in discovering a cure for amyloidosis. We thank our donors for their ongoing participation and commitment. This donor list recognizes individuals who have made gifts

totaling \$250 or more to the Amyloidosis Center between January 2013 and October 2015. We have made every effort to provide a complete and accurate list. We apologize in advance for any errors that may have been made. While space constraints prevent us from listing the names of donors of gifts under \$250, we very sincerely appreciate the support of those many donors.

INDIVIDUAL DONORS

\$100,000 and above
Mr. Melvin R. Berlin and Ms. Randy L. Berlin
Mr. Joseph M. Wikler and Mrs. Madeline Wikler

\$50,000 - \$99,999
Anonymous

\$25,000 - \$49,999
Mr. Thomas A. Green
Mr. Juan De J. Hernandez Batista

\$20,000 - \$24,999
Mr. Samuel Finkelsztain and Ms. Gala Finkelsztain
Mr. Arthur Thomas Katsaros and Mrs. Denise S. Katsaros
Mr. Benjamin A. Newman
Summer Stone, M.D. and Martha Skinner, M.D.

\$10,000 - \$19,999
Anonymous
Mr. Robert D. Champion and Mrs. Marjorie Champion
Mr. Adolf R. Dibiasio and Ms. Josephine Dibiasio
Mr. Clayton W. Frye, Jr.
Mr. Ray A. Garver and Mrs. Donna L. Garver
Mr. Frederick W. Gluck and Ms. Linda J. Gluck
Ms. Julie Hansell
Mr. Ian Hight and Ms. Lea Hight
Mr. Clinton W. Josey and C. W. Josey
Mr. William Patty and Ms. Eliot Patty
Ms. Alyssa Shooshan and Ms. Kate Shooshan
Mr. John G. Shooshan and Mrs. Marcia Shooshan
Ms. Diane Stewart and Ms. Sandra Stewart
Mrs. Eliot Brady Stewart

\$5,000 - \$9,999
Ms. Ann B. Bennett
Mr. Frank Citrone, Jr. and Ms. Carol Citrone
Mr. D. Ronald Daniel and Ms. Lise Scott
Ms. Ineke M. Dikland
Mr. Paul E. Dixon, Jr. and Mrs. Rebecca K. Dixon
Mr. Charles Eddy
Mr. Edward A. Friedman
Mr. Mickey Hubregtzen
F. James Knittle and Gloria G. Knittle
Ms. Suzanne Lehmann
The Estate of Siri J. Markowitz
Ms. Margaret McGrath
Joseph McNelis
Mr. Richard M. Pryor
David C. Seldin, M.D., Ph.D. and Elizabeth L. Hohmann, M.D.
The Estate of Barrie Ruth Straus

\$2,500 - \$4,999
Mrs. Marsha R. Asbury
Mr. Abraham I. Bennett
Scott E. Brown, M.D. and Mrs. Lisa R. Brown
Mr. John W. Carpenter and Ms. Ellen S. Carpenter
Mr. Larry Field and Ms. Barbara Field
Harold W. Forbes, M.D. and Ms. Carol S. Forbes
Mrs. Dorothy M. Green
Mrs. Ruth Ann Homan
Ms. Betsy E. Horen
Mr. Mark Allen Lewis
Ms. Rebecca A. Massey
Mr. Terry R. Peel and Mrs. Ann D. Peel
Mr. Neil Pinsky and Ms. Karen Pinsky
Ms. Sally L. Speer
Ms. Frankie Anne Tester
Mr. Peter S. Wellington

\$2,000 - \$2,499
Ms. Jacklin Bodaghi
Ms. Joan Hadley Crawl
Ms. Anne M. Frasca
Mr. Mark S. Freshwater and Ms. Deborah L. Freshwater
Stephen W. Hildreth
Ms. Sylvia M. LaChapelle and Mr. Kenneth C. LaChapelle
Mr. Alan R. Langille
Mr. Hamilton Lott, Jr. and Mrs. Barbara H. Lott

Sean B. McSweeney and Patricia M. McSweeney
Jonathan G. Smith, M.D. and Ms. Megan Smith
Ms. Cyrille D. Straus
Ms. Barbara R. Trotter and Mr. Robert F. Trotter
Mr. David J. Wallace

\$1,500 - \$1,999
Mr. John F. Folley
Mr. George H. Gallup
Mr. John Garner
Mrs. Betty Joanne Gaver
Mr. Harold J. Kober and Ms. Patricia Kober
Mr. James L. Lerner
Lt. Colonel Gary E. Martilla
Mr. Michael J. Newman and Ms. Suzanne Newman
Mrs. Rita M. O'Neil
Mr. Jordan C. Paul and Mrs. Valerie J. Paul
Mr. Robert W. Potter
Mrs. Ann S. Rosenthal
Katherine E. Rowan, Ph.D. and Mr. Robert Baker
Mrs. Ann L. Schafstedde
Ms. Florence Seldin and Mr. Ira L. Seldin
Mr. Gene Stewart Tyler

\$1,000 - \$1,499
Mr. Edmund F. Armstrong, Jr.
Mr. Helder Assuncao and Mrs. Maria P. Assuncao
Mr. Stewart A. Blanchard and Ms. Shelley A. Blanchard
Mr. Roger M. Brown and Ms. Karen J. Doswell
Ms. Deborah Winston Callard
Mr. David C. Campbell
Mr. Wayne Crandell
Mr. Jeffrey G. Cribbs and Ms. Leanne L. Cribbs
Ms. Lorraine M. Curry
Mr. Timothy F. Desmond and Mrs. Donna M. Desmond
Mr. William H. Edington
Mr. Herbert Elish and Ms. Eloise H. Elish
Mr. John R. Evans, Jr.
Mr. Rick Falzone
Mr. Elliot M. Fiedler
Mr. George A. Finley, III and Ms. Phyllis A. Finley
Mr. Ronald C. Gay and Ms. Rose A. Gay
Ms. Judith Groner
Ms. Janel Newkirk Hutchinson
Mr. John Jaufmann and Ms. Doreen Keane
Mr. Hal S. Jones and Ms. Anne-Lise Auclair-Jones
Mr. C. Monroe Keeney and Mrs. Mary L. Keeney
Mrs. Mary D. Kirchner
Mr. Joseph Kulas
Mr. Edward J. Lenkin and Ms. Roselin Atzwanger
Mr. Alexander Ogedegbe and Ms. Mary Lucchesi
Mr. H. George Mann and Mrs. Roberta G. Mann
Mr. John S. McCleary and Mrs. Linda W. McCleary
Ms. Ilona Melstrads
Mrs. Linda M. Monkell
Mr. Michael M. Monteith
Mr. Steve Mueller and Ms. Tami Mueller
Mr. Roger W. Neal and Mrs. Roberta A. Neal
Mr. Timothy E. Powers and Mrs. Elaine S. Powers
Mr. E. Dennis Ross and Mrs. Marian R. Ross
Mr. David B. Schulman
Ms. Leslie M. Sherr
Mr. Thomas Spann
Mr. Craig J. Stanley and Ms. Carol A. Stanley
Mr. Jeffrey L. Steele and Ms. Barbara B. Steele
Mr. Stephen G. Stein
Ms. Sandra Stewart
Mrs. Susan C. Stoddard
Ms. Kathi J. Vandever
Mrs. Judith L. VanZant
Mr. William Rose and Ms. Marissa Vetrone
Mr. Adrian Washington
Mr. Gary L. Wolf

\$500 - \$999
Mr. Richard Aber, Ms. Asta Thorn, and Mr. and Mrs. Leonard Jasko
Mrs. Fay A. Alpert
Mr. Matthew J. Amerlan and Ms. Erin E. Amerlan
Ms. Ibret Andrade
Anonymous
Mr. Gerald Argabright

Mr. M. William Backus and Ms. Leslie Backus
Ms. Gari Ann Banks
Rabbi Amy D. Bardack and Jared W. Magnani, M.D.
Ms. Judith F. Bardack
Mr. George H. Bass and Mr. Tim C. Bass
Mrs. Sara Ann Beard
Alan M. Berg, M.D. and Ms. Sharon G. Wolpert
Mr. Albert J. Birmingham
Ms. Jan K. Bixler
Mr. Ronald L. Boucek
Reverend Michael J. Burns and Mrs. Linda L. Burns
Mr. William F. Butterfield
Mr. Robert T. Carbone
Mr. Christopher H. Casey and Ms. Annette M. Casey
Mr. Peter Chadwick and Ms. Kirsten A. Chadwick
Ms. Alison Chang
Mr. Christopher Clark and Ms. Katherine Cleaver
Colonel Robert D. Clark
Ms. Patricia G. Cohen
Mr. Patrick H. Collins
Lawreen H. Connors, Ph.D. and Mr. Michael K. Connors
Mr. Richard Corn and Ms. Janis H. Fox
Mr. J. G. Cosgrove
Mr. Stephen J. Davis and Mrs. Kathryn M. Davis
Ms. Anne DeCaire
Mrs. Lena Delligatti
Manishi A. Desai
Mr. Edward Devlin and Ms. Kathleen Devlin
Mr. Wayne L. Dingwell and Ms. Leah E. Dingwell
Mr. Jeffery W. Howe and Ms. Reva M. Dolobowsky
Mr. Peter Dooley
Ms. Anne Dooley Ikeda
Mr. Howard Mark Felt
Mrs. Muriel Finkel and Mr. Stephen D. Finkel
Ms. Elizabeth L. Fleischer
Mr. David A. Frantz
Mr. Bryan D. Fry and Ms. Deedra L. Fry
Ms. Alison Gallup
Casimiro Giampaolo, M.D. and Mrs. Jo Ellen Mistarz
Mr. Arlen Grove
Mr. George S. Harlem and Mrs. Rosina P. Harlem
Ms. Andrea C. Henry
Reverend Norman A. Hjelm
Mr. Jon Hoffman and Ms. Mary Hoffman
Mr. Alexander Hoyle
Dr. Hongbing Huang
Mr. Tom Huffaker and Ms. Claire Huffaker
Mr. Thomas M. Hyndman
Mr. Jack Iliff and Mrs. Sally Iliff
Ms. Sylvia Iliffe
Mr. William Isaacson
Ms. Charisje Keefe James
Mrs. Judith A. Johnson
Ms. Eve M. Kaplan
Ms. Maureen O'Brien Kennedy
Ms. Jill Kent
Mr. Henry L. Levine
Mr. Raymond M. L'Heureux and Mrs. Kathy L'Heureux
Ms. Kimberly G. Litherland
Ms. Loraine S. Livingston and Mr. Frank H. Livingston
Ms. Anne Madden
Ms. Phoebe S. Markey
Ms. Sophia McCroclin
Mr. Sam Scott Miller and Mrs. Mary F. Miller
The Estate of Shawn Miller
Ms. Audrey Morris
Mr. Raymond D. Salvo and Ms. Tamar Myers
Ms. Adina Ness
Ms. Nancy P. Newkirk
Ms. Betty M. Nobel
Mr. Robert J. Nozza and Ms. Wilma T. Nozza
Ms. Mary E. O'Donnell
Mr. Robert J. Owczarek
Mr. Steven J. Pike
Mr. Richard W. Pogue
Mr. George Pollard
Mrs. Lois G. Poucher and Mr. John S. Poucher
Ms. Stella Ann Renaker
Mr. John E. Ritzert and Sandra J. Ritzert
Ms. Anne L. Roe
Mr. Steven B. Rupp
Martin Cherniack, M.D. and Ms. Laurie Santos

Ms. Elizabeth Schwartz
Peter S. Schwedock and Roberta M. Schwedock
Irving Shiffman, M.D.
Ms. Corrine E. Shurte
Ms. Sally W. Simoes
Mr. Lee R. Slosberg and Mrs. Marion Slosberg
Ms. Adrienne G. Smith
Mrs. Cathy K. Smith and Mr. William S. Smith
Ms. Sandra S. Soltis
Ms. Diane M. Sullivan
Ms. Paula Thompson
Ms. Vivian A. Virden
Mr. Ira M. Wallace
Mr. William D. Whitney and Ms. Jean Whitney
Mr. Stephen F. Wright and Ms. Christine Y. Wright
Ms. Maryann Rosenthal Wyner

\$250 - \$499
Ms. Cathy Abelson-Lipshutz and Mr. Bob Lipshutz
Mrs. Lucy Kay Abernathy
Ms. Mary K. Adams and Mr. Stephen E. Adams
Ms. Caroline I. Alpert
Mr. David Baker
Mr. Carl W. Banks
Mr. Robert J. Bartel
Ms. Catherine Beckley
Mr. Dan D. Bell and Mrs. Jan R. Bell
Mr. Robert Benisek and Mrs. Sylvia Benisek
Mr. Florencio Berrios Castrodad
Ms. Maria Birardi
Mr. Paul J. Bollea and Ms. Leslee L. Bollea
Mrs. Janet L. Boyle and Mr. Robert E. Boyle, Jr.
Mr. C. John Bryer
Mr. Edmund S. Burke, Jr. and Mrs. Eleanor O. Burke
Ms. Robyn K. Burnside
Ms. Eileen Calvey
Noran J. Camp
Mr. Alfonso Canedo
Mr. James O. Clark, III and Ms. Annie O. Clark
Mr. Thomas F. Clark and Ms. Kathy L. Clark
Mr. James B. Cohen and Ms. Randi C. Cohen
Mr. Harry Cohen and Ms. Jan Cohen
Mr. John T. Collins and Mrs. Kathleen M. Collins
Mr. Thomas J. Connell and Ms. Dorothy T. Connell
Mr. Robert R. Conway and Mrs. Judith C. Conway
Mr. Kevin W. Copeland
Mr. and Mrs. Michael Costello
Richard W. Cribbs, D.D.S.
Ms. Jennifer C. Davis
Mr. Stephen A. DeCubellis and Ms. Frances D. DeCubellis
Mr. Thomas J. DeSimone and Ms. Mary DeSimone
Mr. Robert J. Detrick
Mr. David Dible and Ms. Gloria Dible
Mr. Mark DiMaurizio
John M. Doggett and Patricia H. Doggett
Ms. Patricia L. Eaton
Mr. David A. Elliott and Ms. Gail A. Elliott
John Emerson, Ph.D. and Mrs. Amy J. Emerson
Mr. Edward Englander and Ms. Linda Englander
Mr. James Engle and Ms. Robin Engle
Mr. Anthony F. Essaye and Ms. Eileen F. Essaye
Mrs. Bernice E. Felix
Mr. Michael Ferraro and Mr. Denis Ferraro
Mr. Stephen A. Fisch and Ms. Jenifer A. Fisch
Ms. Valerie Fischler
Mr. Eric Folley and Mrs. Mary Folley
Mr. James W. Foster
Mrs. Karen Fowler
Mr. Robert T. Fowler
Mr. Adel T. Foz and Ms. Blanche M. Foz
Ms. Luule French
Mr. Richard Friedman and Ms. Roberta A. Friedman
Mr. David Garnett
Mr. Wayne Gilman and Mrs. Debra Gilman
Honorable Susan Golding
Ms. Patricia M. Goward
Mr. George W. Grant
Mr. Arthur J. Griffa and Mrs. Barbara H. Griffa
Mr. Charles F. Grimes and Ms. Patricia B. Grimes
Mrs. Karen Gail Grimm
Mr. Jonathan P. Hains
Sanford I. Hansell and Raina M. Ernstoff Hansell

Ms. Lisa Harris and Mr. Timothy Beutel
Mr. Jay V. Hebert and Ms. Ann M. Hebert
Ms. Darcy J. Hickey
Ms. Heidi M. Hohmann
Mr. William N. Hoover and Mrs. Kari M. Hoover
Mr. Robert A. Horen
Robert Ingel and Mrs. Martha L. Ingel
Mr. Richard B. Johns, Jr. and Mrs. Carol A. Johns
Ms. Patricia T. Judice
Mr. Peter Kaplan
Gary Karlin, M.D. and Ms. Jane Zamost
Mr. Earle W. Kazis
Mr. David J. Kerness
Ms. Tracy King
Ms. Kimberly Klimek and Mr. David Klimek
Ms. Corrine Knab and D. Knab
Robert P. Kreminski and Barbara R. Kreminski
Mr. Holger Krogemann
Mr. Albert Kwok
Mrs. Marie Lennon
Mr. Brian J. Leonard and Ms. Sidney Leonard
Mr. Donald R. Lomb and Ms. Mary A. Lomb
Mr. Peter R. Loughlin and Ms. Valerie Loughlin
Mr. Robert Major and Ms. Michelle L. Major
Rosemary Mazant and John G. Stoecker
Ms. Alison Mencer
Ms. Nina B. Mintzer
Mr. Gary Moebus
Mr. Edward L. Morton, Jr. and Ms. Janet L. Morton
Mr. Frank Nappi and Ms. Julie A. Nappi
Ms. Tracey Nautel
Ms. Leslie B. Neustadt
Ms. Dolores C. Nocera
Ms. Elise E. Nollenberger
Mrs. Barbara Noymer
Mr. Fritz S. Noymer and Mrs. Luciana S. Noymer
Mrs. Constance O'Brien
Ms. Jeanne O'Brien and Mr. Forrest W. O'Brien
Mr. Bruce L. Paisner
Mr. James Pazzanese and Ms. Kate Grimes
Mr. James E. Penders and Mrs. Joan C. Penders
Ms. Cynthia Peters
Tania J. Phillips, M.D. and Jeffrey S. Dover, M.D.
Mr. Thomas W. Raymond
Ms. Noreen Riordan
Mrs. Elizabeth Nagle Rizzuto
Mr. Bruce Rosenberg and Ms. Jane Rosenberg
Mr. Mark C. Rouvalis and Mrs. Cynthia J. Rouvalis
Mr. Michael J. Salkas and Ms. Judith C. Salkas
Ms. Dorinda M. Cosimano and Mr. James R. Schiffer
Mr. Todd E. Schlegel and Ms. Julia J. Schlegel
Mr. Leslie Schlessinger
Mr. Victor C. Schlitzer
Mr. Jeff Schwartz and Ms. Jamie Schwartz
Mr. William H. Seyler and Ms. Shirley A. Seyler
Mrs. Ruby Shalansky
Mr. Richard A. Shapiro and Ms. Jane Shapiro
Mr. Daniel L. Shaw
Mr. Joseph R. Shea
Richard D. Sherr, Ed.D. and Ms. Carole A. Sherr
Ms. Sheryl Short
Mr. Kenneth T. Siloac and Mrs. Sharon A. Siloac
Mr. Michael L. Silverman
Mr. Frederick A. Slack, IV
Mr. Kirby Slack
Mr. Frederick Slack, III and Ms. Susan Slack
Mr. John Small
Mr. Brian D. Smith
Ms. Edith E. Sorrentino
Mr. Robert J. Stein and Mrs. Joan L. Stein
Mr. Thomas Steinmetz
Mr. David Sterman
Mr. Stephen F. Stettler
Mr. Jamie Still
Mr. Steven R. Finley and Ms. Linda Stillman
Elizabeth Bloomberg Sullivan
Mr. A. R. Van Doren, Jr. and Ms. M. A. Van Doren
Mr. Thomas Watson and Mr. Gerald Laudato
Ms. Diane C. Webster
Mr. Bruce Weimar and Ms. Cindy Weimar
Janice Wiesman, M.D.
Mr. Ronald Williamson

Mr. David J. Winton
Ms. Anneli Wrething
Ms. Catherine E. Zadoretzky
Mr. Walter C. Zampella and Mrs. Hildy J. Zampella


† Deceased

CORPORATIONS AND FOUNDATIONS

Alexandria Capital, LLC.
ALNYLAM US, Inc.
Amyloidosis Support Groups, Inc.
Arbella Insurance Group
Arlington Community Foundation
Anonymous
Bill & Melinda Gates Foundation
Camargo Cadillac Company
Chen Living Trust
David Seldin Trust
Delaware Community Foundation
Dick Bounds Memorial Horseshoe Tournament
Electronic Interiors, Inc.
EMC Insurance Companies
EverSource Energy
Ferraro Properties, LLC
Frank Citrone Research Fund
Garrett Living Trust
GE Energy Financial Services
General Electric Company
Great-West Life Assurance Company
IBM
iMedia Technology
Jones Day
Katsaros Family Foundation
MasterCard International, Inc.
NBCUniversal Media LLC
Northern Trust Charitable Giving Program at the Chicago Community Foundation
Oppenheimer Funds Inc.
P & E Davidian Rev. Trust
Pfizer, Inc.
Primo Painting Contracting Corp
Renaissance Charitable Foundation, Inc.
Robert Wood Johnson University Hospital
Schwab Charitable Fund
Sea Port Marine Corporation
SFSG
Shiseido Co. Ltd.
Stamford Hospital
Stanwood Capital Group Management, L.L.C.
Steven B. Rupp Living Trust
T. Rowe Price Program For Charitable Giving
The Barbara A. Noymer Trust
The Continued Fight LLC
The Daniel Z. Weida Family Living Trust
The Irving T. Bush Foundation, Inc.
The Jeanne & Herbert Hansell Fund
The R. K. and L. M. Sherr Joint Rev. Trust
The WMY Fund
The Women's Group of the Greens, Inc.
Thurston Community Players
Universal Printing Company LLC

FUNDRAISERS

Dick Bounds Memorial Horseshoe Tournament
Faculty & Staff at the Harvard Med School - Global Health and Social Medicine
Friends of Carl Banks
Friends of Leslie Sherr
Friends of Mary Miliano
Friends of Noel Bodaghi Family
John Tempest Memorial Golf Tournament
Nassau Wings Motor Cycle Club, Inc.
Staff of Port Byron Teachers Assoc.
Walk For An Angel Fund



AMYLOIDOSIS CENTER REPORT

FALL 2015 | ISSUE 29
www.bu.edu/amyloid

AMYLOIDOSIS CENTER

72 East Concord Street, K-503
Boston, MA 02118

Phone 617.638.4317

Fax 617.638.4493

Email amyloid@bmc.org

Website www.bu.edu/amyloid

The Amyloidosis Center gratefully accepts financial support for our research and clinical programs from patients, family, and friends.


For more information on bequests and other planned giving options contact us at the address listed above or by phone.

Donations can be made through our website or by mail.


NON-PROFIT
U.S. POSTAGE
PAID
BOSTON, MA
PERMIT NO. 1839



Amyloidosis Center




Friday research meeting



Brian Spencer, Amyloid Laboratory



Dr. Hassan Yameen



Dr. Haili Cui, Amyloid Laboratory